Orabloc (articaine/epinephrine) / Pierrel - LARVOL DELTA

LA AGENTS: Assessment of Local Anaesthesia Effectiveness in Symptomatic Irreversible Pulpitis (clinicaltrials.gov) - P2 | N=123 | Completed | Sponsor: 28 Military Dental Centre Lahore

New P2 trial • Anesthesia • Dental Disorders

Comparative Evaluation of Alveolar Nerve Block with 2% Lidocaine-Epinephrine and 4% Articaine-Epinephrine Buccal Infiltration in Mandibular Premolar and Molar Region in Children: A Double-Blind, Randomized Trial. (PubMed, Children (Basel)) - "Articaine also outperformed lidocaine in secondary measures, with higher positive responses on the questionnaires (articaine: 8.37 ± 1.61 vs. lidocaine: 5.27 ± 1.41, p < 0.001). Buccal infiltration with 4% articaine is more effective than 2% lidocaine administered via IANB for invasive dental procedures in children, providing superior pain control and positive patient responses."

Journal • Anesthesia • Pain • Pediatrics

IANB: Different Volumes of Articaine for Inferior Alveolar Nerve Block in Irreversible Pulpitis (clinicaltrials.gov) - P2 | N=78 | Completed | Sponsor: Armed Forces Institute of Dentistry, Pakistan | Recruiting ➔ Completed | Trial completion date: Oct 2023 ➔ Jul 2024 | Trial primary completion date: Oct 2023 ➔ Jul 2024

Trial completion • Trial completion date • Trial primary completion date • Anesthesia • Dental Disorders

Patient discomfort and intensity of intraseptal anesthesia of computer-controlled articaine/epinephrine delivery for scaling and root planing. (PubMed, Clin Oral Investig) - P=N/A | "The pain during ISA administration was mild and well tolerated regardless of the anesthetic dose. A lower intensity of pain during SRP can be expected in patients with greater CAL. Post-treatment pain can be anticipated after SRP in the regions with greater PPD and CAL."

Journal • Anesthesia • Pain

IANB: Different Volumes of Articaine for Inferior Alveolar Nerve Block in Irreversible Pulpitis (clinicaltrials.gov) - P2 | N=78 | Recruiting | Sponsor: Armed Forces Institute of Dentistry, Pakistan

New P2 trial • Anesthesia • Dental Disorders

Comparative Study between the Combination of Dexamethasone and Bupivacaine for Third Molar Surgery Postoperative Pain: A Triple-Blind, Randomized Clinical Trial. (PubMed, J Clin Med) - "Objectives: To compare the possible benefits of the combination of dexamethasone-bupivacaine with articaine-epinephrine as an anaesthetic block after third molar surgery. Drug consumption was lower in the experimental group throughout the study period (p < 0.04). Bupivacaine is an alternative to articaine in oral surgery, being more effective in reducing postoperative pain by reducing patients' scores on the VAS as well as their consumption of analgesic drugs after surgery."

Clinical • Journal • Anesthesia • Pain

The effect of single buccal infiltration anesthesia of 4% articaine with either 1:100,000 or 1:200,000 epinephrine on pulpal blood flow and anesthesia of maxillary first molars and second premolars in humans. (PubMed, Clin Oral Investig) - "Single buccal infiltration to maxillary first molar is potent enough for pulpal and buccal tissue anesthesia, except palatal tissue anesthesia, in both first molar and second premolar."

Journal • Anesthesia

Italy’s Pierrel Pharma obtains marketing authorisation for Orabloc in Bulgaria (SeeNews) - "Italian pharmaceutical company Pierrel said on Wednesday that through its subsidiary Pierrel Pharma it has obtained marketing authorisation for the dental anaesthetic Orabloc in Bulgaria."

European regulatory • Anesthesia

Pierrel S.p.A.: Approval on a voluntary basis of the interim management report for the Pierrel Group and Pierrel S.p.A. at 31 March 2020 (Market Screener) - "Results at 31 March 2020 affected, both in terms of revenues and EBITDA, by the postponement in the first days of April 2020 of the shipment of some batches of Orabloc, due to logistical problems due to the ongoing health emergency, but already recovered at the end of the first quarter of 2020, whose data are in line with both the results achieved by the Group at 30 April 2019 and the budget forecasts, which have been confirmed for the whole year 2020."

Commercial • Anesthesia

FDA approved drug products (FDA) - Initial U.S. Approval: 2000

NDA